Thought Leadership & Publications

Reframing Pharmaceutical Localization for Resilient Health Systems 

April 2026 Status: Manuscript submitted to Communications Health; under review.              

Request access to download the actionable insights? ⬇️

Executive Summary Global efforts to localize biopharmaceutical manufacturing are accelerating, but many capital-intensive initiatives stall due to a focus on industrial policy over health-system implementation. This leads to a "capability trap" characterized when governments or sovereign wealth funds authorize massive, over-specified infrastructure projects that mirror state-of-the-art facilities in the Global North - where physical infrastructure construction outpaces workforce capability, regulatory maturity, and quality readiness, risking the creation of expensive stranded assets.

In this paper, Jacob Hallengreen proposes a fundamental paradigm shift: a disciplined, stage-gate delivery architecture governed by a neutral "Integrator" operating as a boundary organization. 

The paper introduces the Minimum Viable Solution for Localization (MVS-L), underpinned by Real Options Analysis (ROA). By explicitly tying modular capacity expansion to verified, pooled public demand, the MVS-L framework de-risks initial capital expenditure and preserves strategic flexibility. Ultimately, reframing localization through this integrated systems-engineering lens provides an actionable blueprint to transform political ambitions into sustained, resilient access to essential therapeutics.